Corvus Pharmaceuticals, Inc. Fair Value Adjustment of Warrants
Corvus Pharmaceuticals, Inc. (CRVS) reported Fair Value Adjustment of Warrants of -$27.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Corvus Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Corvus Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2025-06-30 was -$2.01M.
- Corvus Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2025-03-31 was -$25.13M.
- Corvus Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2025 was -$27.14M, a 181.32% decline from fiscal 2024.
- Corvus Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2024 was $33.38M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 6 month as first filed | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 9 month as first filed | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | -$2.01M derived: sum of 3 quarters · filed 2026-08-06 | -$27.14M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.01M derived: sum of 2 quarters · filed 2026-08-06 | -$27.14M 10-Q · filed 2025-11-04 | -$24.79M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$2.01M 10-Q · filed 2026-08-06 | -$27.14M 10-Q · filed 2026-08-06 | -$24.79M derived: sum of 3 quarters · filed 2026-08-06 | $8.05M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$25.13M 10-Q · filed 2026-05-07 | -$22.78M derived: sum of 2 quarters · filed 2026-05-07 | $10.06M derived: sum of 3 quarters · filed 2026-05-07 | $8.25M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $35.19M derived: sum of 2 quarters · filed 2026-03-12 | $33.38M derived: sum of 3 quarters · filed 2026-03-12 | $33.38M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $32.85M 10-Q · filed 2025-11-04 | -$32.80M 10-Q · filed 2024-11-12 | $31.03M derived: sum of 2 quarters · filed 2025-11-04 | $31.03M 10-Q · filed 2025-11-04 | -$31.03M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | -$1.82M 10-Q · filed 2025-08-07 | $1.80M 10-Q · filed 2024-08-06 | -$1.82M 10-Q · filed 2025-08-07 | $1.82M 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |